Launch your #ADAA2019 experience with an inspiring keynote address:
Potential Drugs of Abuse as Antidepressants and Anxiolytics: Pluses and Minuses
Thursday, March 28, 2018 - 5:45 - 7:00 pm
Increasing data from research studies point to potential drugs of abuse as antidepressants and anxiolytics. This presentation reviews recent data and raises key issues regarding how to balance risk-benefit both for individual patients and society at-large.
Dr. Schatzberg received his MD from New York University. He did his psychiatric residency at Harvard Medical School, Massachusetts Mental Health Center where he was later a Professor of Psychiatry before becoming the Kenneth T. Norris, Jr. Professor and Chair at Stanford. Dr. Schatzberg has been an active investigator in the biology and psychopharmacology of depressive disorders and has authored over 700 publications and abstracts. He has been President of the American College of Neuropsychopharmacology, the Society of Biological Psychiatry, and the American Psychiatric Association, and has received numerous national and international awards.
Dr. Schatzberg - Recent News Stories
New Ketamine-Based Antidepressant Nasal Spray Sparks Criticism, Westsidestory.com, March 22, 2019
FDA May Give A ‘Go Ahead’ To Esketamine For Severe Depression, GlobalNewsJournal.com, March 18, 2019
What Makes the Newly Approved Drug for Depression so Different?, Livescience.com, March 6, 2019
FDA Approves Ketamine-Like Drug for Severe Depression, Healthday.com, March 6, 2019
FDA Poised to Approve Ketamine Like Drug to Ease Depression, Healthday.com, March 5, 2019
Interested in sponsoring the 2019 Keynote Address? Contact Gabby Oved for more details.
Opening Session Brought to you by Rogers Behavioral Health